Stock of the Day

Eli Lilly and Company (LLY)

$1,151.92

-$8.16 (-0.7%)

Market Cap: $1.08T

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company Bull Case

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

• The company recently reported earnings per share (EPS) of $8.38, significantly exceeding analysts' expectations, indicating strong financial performance.
• Eli Lilly and Co has a robust net margin of over 33%, suggesting efficient management and profitability, which can lead to higher returns for investors.
• The stock has shown impressive revenue growth, with a year-over-year increase of nearly 48%, reflecting strong demand for its products.
• The current stock price is around $1,190, which is near its twelve-month high, indicating strong market confidence in the company's future prospects.
• The company has a solid dividend payout ratio of 23.22%, providing a steady income stream for investors through its quarterly dividends.

Eli Lilly and Company Bear Case

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

• The stock has a relatively high price-to-earnings (P/E) ratio of 39.23, which may suggest that it is overvalued compared to its earnings potential.
• With a beta of 0.51, the stock is less volatile than the market, which may limit potential gains during bullish market conditions.
• The company has a debt-to-equity ratio of 1.41, indicating a higher level of debt compared to equity, which could pose risks in economic downturns.
• Insider selling activity has been noted, with significant shares sold recently, which may raise concerns about the company's future outlook from those closest to it.
• The dividend yield is relatively low at 0.6%, which may not be attractive for income-focused investors compared to other investment opportunities.

Recent News

• Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress (finance.yahoo.com)
• Eli Lilly Just Announced a Major Acquisition. Here's What It Means. (fool.com)
• Eli Lilly Just Announced a Major Acquisition. Here's What It Means. (fool.com)
• Lilly’s Record Stock Price Is Hiding an Even Bigger Opportunity (247wallst.com)
• Lilly's Record Stock Price Is Hiding an Even Bigger Opportunity (247wallst.com)
• Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity (marketbeat.com)
• This New Zepbound Study Could Be Great News for Eli Lilly Investors (fool.com)
• This New Zepbound Study Could Be Great News for Eli Lilly Investors (fool.com)
• Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet (247wallst.com)
• Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference (prnewswire.com)